CN115867310A - 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 - Google Patents

用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 Download PDF

Info

Publication number
CN115867310A
CN115867310A CN202180042266.0A CN202180042266A CN115867310A CN 115867310 A CN115867310 A CN 115867310A CN 202180042266 A CN202180042266 A CN 202180042266A CN 115867310 A CN115867310 A CN 115867310A
Authority
CN
China
Prior art keywords
seq
specific binding
binding molecule
tcr
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042266.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·奇拉库里
A·普尔
S·贝利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of CN115867310A publication Critical patent/CN115867310A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180042266.0A 2020-05-05 2021-05-04 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 Pending CN115867310A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006629.6A GB202006629D0 (en) 2020-05-05 2020-05-05 Specific binding molecules
GB2006629.6 2020-05-05
PCT/EP2021/061731 WO2021224261A1 (en) 2020-05-05 2021-05-04 Soluble tors and fusions to anti-cd3 recognising kras g12d for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN115867310A true CN115867310A (zh) 2023-03-28

Family

ID=71080372

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042266.0A Pending CN115867310A (zh) 2020-05-05 2021-05-04 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物

Country Status (8)

Country Link
US (1) US20230348595A1 (https=)
EP (1) EP4146257A1 (https=)
JP (1) JP7682927B2 (https=)
CN (1) CN115867310A (https=)
AU (1) AU2021267361A1 (https=)
CA (1) CA3181362A1 (https=)
GB (1) GB202006629D0 (https=)
WO (1) WO2021224261A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217538A1 (zh) * 2023-04-19 2024-10-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
WO2024222850A1 (zh) * 2023-04-26 2024-10-31 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
WO2024222933A1 (zh) * 2023-04-28 2024-10-31 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
WO2025124489A1 (zh) * 2023-12-14 2025-06-19 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN120647748A (zh) * 2025-05-16 2025-09-16 浙江大学 一种活性提升的tcr及其用途
WO2025189363A1 (zh) * 2024-03-12 2025-09-18 广州医科大学 一种t细胞受体(tcr)及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201901305D0 (en) * 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574906A (zh) * 2009-07-03 2012-07-11 英美偌科有限公司 T细胞受体
CN106414482A (zh) * 2013-08-12 2017-02-15 英美偌科有限公司 T细胞受体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
MXPA02005559A (es) 1999-12-06 2004-09-10 Univ Illinois Proteinas de tcr de alta afinidad y metodos.
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US11827688B2 (en) 2016-06-02 2023-11-28 Immunocore Limited Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574906A (zh) * 2009-07-03 2012-07-11 英美偌科有限公司 T细胞受体
CN106414482A (zh) * 2013-08-12 2017-02-15 英美偌科有限公司 T细胞受体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATHANIEL LIDDY ET AL.: "Monoclonal TCR-redirected tumor cell kiIIing", NATURE MEDICINE, vol. 18, no. 6, 6 May 2012 (2012-05-06), pages 980 - 987, XP055241791, DOI: 10.1038/nm.2764 *
Q. J. WANG ET AL.: "Identification of T-cell Receptors Targeting KRAS- Mutated Human Tumors", CANCER IMMUNOLOGY RESEARCH, vol. 4, no. 3, 1 March 2016 (2016-03-01), pages 204 - 214, XP055314168, DOI: 10.1158/2326-6066.CIR-15-0188 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217538A1 (zh) * 2023-04-19 2024-10-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
WO2024222850A1 (zh) * 2023-04-26 2024-10-31 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
WO2024222933A1 (zh) * 2023-04-28 2024-10-31 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
WO2025124489A1 (zh) * 2023-12-14 2025-06-19 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
WO2025189363A1 (zh) * 2024-03-12 2025-09-18 广州医科大学 一种t细胞受体(tcr)及其用途
CN120647748A (zh) * 2025-05-16 2025-09-16 浙江大学 一种活性提升的tcr及其用途
CN120647748B (zh) * 2025-05-16 2026-03-06 浙江大学 一种活性提升的tcr及其用途

Also Published As

Publication number Publication date
EP4146257A1 (en) 2023-03-15
JP2023524788A (ja) 2023-06-13
GB202006629D0 (en) 2020-06-17
WO2021224261A1 (en) 2021-11-11
AU2021267361A1 (en) 2022-12-15
JP7682927B2 (ja) 2025-05-26
US20230348595A1 (en) 2023-11-02
CA3181362A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
JP7720685B2 (ja) Ｔ細胞レセプター
CN109563148B (zh) T细胞受体
JP7682927B2 (ja) 特異的結合性分子
ES2965715T3 (es) Receptores de células T
CN115052885A (zh) 特异性结合分子
US20250129161A1 (en) HIV Specific Binding Molecules and Uses Thereof
CN115803339A (zh) 特异性结合分子
US12103971B2 (en) HIV specific binding molecules
CN113874393B (zh) 对hbv包膜蛋白具有特异性的结合分子
RU2825837C2 (ru) Специфичные связывающие молекулы
CN118715240A (zh) Hiv特异性结合分子和tcr

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination